Pfizer’s BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer

Cohort 3 analysis from the BREAKWATER study shows objective response rate of 64% with BRAFTOVI plus cetuximab and FOLFIRI compared to 39% with standard-of-care treatment FOLFIRI with or without bevacizumab The BREAKWATER study demonstrates clinically meaningful and statistically significant results, which show potential flexibility in chemotherapy backbone for patients with BRAF V600E-mutant metastatic colorectal cancer … [Read more…]

Edwards Comments on JenaValve Acquisition

IRVINE, Calif.–(BUSINESS WIRE)–Edwards Lifesciences (NYSE: EW) today announced that the U.S. District Court for the District of Columbia has granted the motion from the U.S. Federal Trade Commission (FTC) for an injunction blocking the company’s proposed acquisition of JenaValve Technology. As a result, Edwards will not acquire JenaValve. Edwards disagrees with the decision and believes … [Read more…]

Assertio Announces Publication of Rolvedon® Same-Day Dosing Clinical Trial

Peer-reviewed publication in “The Oncologist” is now available online Investigational same-day dosing of Rolvedon demonstrated a clinical response and adverse event profile similar to next-day dosing LAKE FOREST, Ill.–(BUSINESS WIRE)–Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that results of a clinical trial investigating a novel dosing schedule of Rolvedon® (eflapegrastim-xnst) injection … [Read more…]

Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets

Vida has partnered with Aktis since co-leading its Series A, supporting the company from discovery through IPO and establishing itself as one of Aktis’ largest shareholders; Helen Kim, Vida Senior Managing Director, has served on the Board since 2021 Brian Goodman, Ph.D., Managing Director at Vida Ventures and Co-Founder of Aktis, served as founding Chief … [Read more…]

University of Pennsylvania, BioNTech, and OUP Launch $50 Million Life Sciences Fund

New venture capital fund will back early-stage life science startups translating Penn biomedical research into life-changing products PHILADELPHIA–(BUSINESS WIRE)–The University of Pennsylvania (“Penn”), BioNTech SE (“BioNTech”), and OUP (Osage University Partners) announced the launch of the $50 million Penn-BioNTech Innovative Therapeutics Seed Fund (“PxB Fund”), a dedicated venture capital fund focused on early-stage life science … [Read more…]

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs BEIJING & ALAMEDA, Calif. & TAIPEI, Taiwan–(BUSINESS WIRE)–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable … [Read more…]

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies GHENT, Belgium–(BUSINESS WIRE)–#Parkinson–MRM Health NV, a … [Read more…]

Johnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation Investments

Voluntary agreement will allow millions of Americans to purchase medicines at significantly discounted rates Agreement provides Johnson & Johnson pharmaceutical products an exemption from U.S. tariffs Company announces two new additional manufacturing facilities to be built in North Carolina and Pennsylvania; continues to deliver on $55 billion U.S. investment NEW BRUNSWICK, N.J.–(BUSINESS WIRE)–Johnson & Johnson … [Read more…]

FineHeart Secures €83 Million to Support Its Growth and Establish Itself as a Future European Leader in Active Implantable Medical Devices (AIMDs)

€35 million Series C funding to accelerate the clinical and industrial development of FlowMaker® €48 million in grants from the IPCEI Tech4Cure program to structure the European Active Implantable Medical Devices (AIMD) sector BORDEAUX, France–(BUSINESS WIRE)–FineHeart, a clinical-stage medical technology company specializing in the development of innovative solutions for cardiology, announced today the completion of … [Read more…]

New Year, New You: Walmart Launches Better Care Services and Rolls Back Prices on 1,000+ Wellness Essentials

BENTONVILLE, Ark.–(BUSINESS WIRE)–Walmart is starting the new year by making healthcare easier and more affordable with the launch of Better Care Services. This one-stop digital destination is designed to help empower millions of customers to take control of their health journeys with ease, transparency and confidence. “We know that when heath care feels hard, many … [Read more…]